04.02.2013 Views

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(12)<br />

(19)<br />

(22)<br />

PATENT APPLICATION PUBLICATION<br />

INDIA<br />

Date <strong>of</strong> filing <strong>of</strong> Application:26/12/2002<br />

(21)<br />

(43)<br />

Application No.: IN/PCT/2002/01292/DEL<br />

Publication Date:09/06/2006<br />

(54) Title <strong>of</strong> <strong>the</strong> Invention:. LIPOSOMAL BENZOQUINAZOLINE THYMIDYLATE SYNTHASE INHIBITOR<br />

FORMULATIONS.<br />

(51) International Classification : A61K 9/127<br />

(31) Priority Document No.<br />

:<br />

60/210,592<br />

(32) Priority Date : 09/09/2000<br />

(33) Name <strong>of</strong> priority country US<br />

(86) International application No. : PCT/US01/18224<br />

Filing Date : 06/06/2001<br />

(87) International Publication No. : WO 01/95884<br />

(61) Patent <strong>of</strong> Addition to<br />

Application No.<br />

:<br />

N.A.<br />

(62) Divisional to Application No. : N.A<br />

Filed On :<br />

Total No. Pages : 84<br />

(71)Name <strong>of</strong> Applicant: OSI<br />

PHARMACEUTICALS, INC<br />

Address <strong>of</strong> <strong>the</strong> Applicant:<br />

Suit 110, 58 South Service Road,<br />

Melville, New York 11747, USA.<br />

(72) Name <strong>of</strong> <strong>the</strong> Inventor: :<br />

CLAUDINE S. ASHVAR<br />

SU-MING CHIANG<br />

DAVID L. EMERSON<br />

NING HU<br />

GERARD M. JENSEN<br />

Filed U/S 5(2) before The <strong>Patents</strong><br />

(Amendment) Ordinance, 2004 : NO<br />

(57) Abstract: Liposomal encapsulated benzoquinazoline thymidylate synthase inhibitor formulations are provided. The liposomes<br />

have improved pharmacokinetics and enhanced efficacy as anti-tumor agents compared to <strong>the</strong> free drug. The formulations<br />

include liposomes comprising at least one phosphatidylcholine, a cholesterol, and a benzoquinazoline thymidylate synthase<br />

inhibitor.<br />

The Patent Office Journal 09/06/2006 11123<br />

A

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!